Is INAB or INCY more undervalued in 2026?

CirclFi compares IN8bio, Inc. (INAB) and Incyte Corporation (INCY) using 13 institutional-grade valuation models. INAB has a Quality of Company score of 3.2/10 while INCY scores 6.4/10.

Which is a better buy — INAB or INCY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do INAB and INCY valuations compare?

INAB at $1.80 and INCY at $97.50 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

INAB vs INCY Valuation Comparison 2026 — Intrinsic Value Analysis

INAB

Biotechnology

IN8bio, Inc.

Quality

3.2

out of 10

Value Trap

LOW

Price

$1.80

Last close

Models

7/13

Active

INCY

Biotechnology

Incyte Corporation

Quality

6.4

out of 10

Value Trap

SAFE

Price

$97.50

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	INAB Fair Value	INAB Upside	INCY Fair Value	INCY Upside
Bayesian DCF	Intrinsic	$1.60	-10.9%	$48.88	-49.9%
Earnings Power Value	Intrinsic	—	—	$86.80	-11.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.60	+99.9%	$26.71	-72.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for INAB vs INCY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INAB vs INCY — Which Stock Is More Undervalued?

INCY scores higher with a 6.4/10 quality rating vs INAB's 3.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing IN8bio, Inc. (INAB) and Incyte Corporation (INCY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INAB currently trades at $1.80 with a QOC of 3.2/10, while INCY trades at $97.50 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).